Navigation Links
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Date:9/10/2009

MOUNTAIN VIEW, Calif., Sept. 10 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it will present analysis of data from the efficacy portion of the first Phase 3 trial of its novel LEVADEX(TM) orally inhaled migraine therapy, currently in development, at the 14th Congress of the International Headache Society. Data from this Phase 3 trial show the potential of LEVADEX to be effective in treating acute migraine as well as a broad spectrum of migraine, including migraine subpopulations that are often resistant to current therapies such as triptans, migraine with moderate and severe pain, migraine with nausea and vomiting and migraine with and without aura.

"A majority of patients are dissatisfied with their current migraine treatment due in part to inconsistent response, high rates of recurrence of the migraine attack within 24 hours and slow onset of action," said Stewart Tepper, M.D., Director of Research for the Center for Headache and Pain, Cleveland Clinic. "Based on these Phase 3 data, LEVADEX has the potential to provide rapid and sustained pain relief, along with a favorable tolerability profile. In addition, LEVADEX showed efficacy in a broad spectrum of migraine subpopulations that are often unresponsive to current migraine therapies."

As previously reported, LEVADEX met all four co-primary endpoints, as well as a number of secondary endpoints, in the first of two Phase 3 clinical trials. The four co-primary endpoints at two hours were:

  • pain relief (p<0.0001);
  • phonophobia free (p<0.0001);
  • photophobia free (p<0.0001); and
  • nausea free (p=0.02).

Results from the post-hoc analyses reported today
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Hearing health affects a ... younger, and remain socially and professionally engaged, he should address ... overriding message that the Better Hearing Institute (BHI) ... National Men,s Health Week , which leads up to ... runs from June 10 through June 16. ...
(Date:5/23/2013)...  A recently published clinical study conducted at TOPS ... , demonstrates that 3D mammography (breast tomosynthesis) significantly reduces ... The study, "Implementation of Breast Tomosynthesis in a ... Stephen L. Rose , MD, and ... Journal of Roentgenology (AJR). The AJR is the ...
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... -- Phase II,results exceed expectations - Alchemia prepares ... company Alchemia Limited will,commence discussions with the US ... of the Phase II clinical trial,of its metastatic ... from the randomized Phase II clinical trial in ...
... data on Eloxatin(R), Taxotere(R) and on three investigational,agents ... at the 43rd,annual ASCO meeting, BRIDGEWATER, N.J., May ... total of 375 abstracts,indicative of its oncology commitment ... the American Society of Clinical Oncology,(ASCO) in Chicago, ...
Cached Medicine Technology:Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 2Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 3Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12
(Date:5/24/2013)... 2013 BroadConnect Telecom, the nation’s ... and IT security solutions, present small to midsized ... by more than fifty percent (when compared to ... PBX Bundle Pricing. BroadConnect’s hosted Voice solutions are ... VoIP. , Starting today, until the end of ...
(Date:5/24/2013)... 24, 2013 With today’s levels of weight ... for advice on the causes of weight gain and how ... that suggest causes of weight gain and treatments that will ... was released by the Child Study Center at NYU ... childhood diagnosis of ADHD and the soring rates of obesity ...
(Date:5/24/2013)... Wednesday, 15th May 2013 | 10am BST | ... webinar playback: http://bit.ly/10Rt0ZH , Ongoing regulatory changes are ... the globe and particularly in Europe, a number of these ... . For dealmakers, understanding how the likes of Basel iii, ... your corner of the market will give you a competitive ...
(Date:5/24/2013)... IMED Mobility, a premier provider of wheelchair vans ... Michelle Murray on Thursday, June 20th 2 p.m to 5 p.m. ... and movie tour, which shares the story of Sam Schmidt, an ... in 2000. Much of the film takes place on the racetrack, ... INDYCAR racing despite suffering a crash that left him paralyzed. In ...
(Date:5/23/2013)... Sublime Beauty® is introducing its ... line, with a 35% discount through May 31st. ... proprietary products, the Cellulite Whisperer® Gel ... receive a report "Getting Control of Your Cellulite" ... wonderful grapefruit scent," says Kathy Heshelow, founder of ...
Breaking Medicine News(10 mins):Health News:BroadConnect Is Offering New Hosted PBX Bundle Pricing for New Customers, Eliminating VoIP Adoption Barriers 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Now Help Patients with Weight Gain Linked to Childhood ADHD Lose Weight Fast 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 3Health News:Local Mobility Dealer Hosts Nashville Recording Artist 2Health News:Fresh Organics in the New Cellulite Whisperer® Products from Sublime Beauty®; "Get Ready for Summer Sale" Continues 2
... WINNIPEG, June 30 /PRNewswire/ - Winnipeg-based medical device ... the 21st Century Achievement Award during the Computerworld ... in Washington D.C. IH Systems received the award ... Automation), the world,s first solution combining software, robotics ...
... 30 The Renal Physicians Association (RPA) supports Kidney ... in Kidney Care (PEAK) initiative. RPA is a member ... dialysis providers, physicians, manufacturers, and nurses who work together ... The goal of the PEAK campaign is to reduce ...
... that chronic disease in either a mother or father ... associated with the development of polycystic ovarian syndrome (PCOS) ... of women with PCOS and insulin resistance are themselves ... suggesting that factors associated with the condition can be ...
... have a diminished number of eggs in their ovaries, either ... as ovarian surgery, may be more at risk of a ... normal, fertile range. Trisomic pregnancies occur when the embryo ... two. The most common trisomy is Down,s syndrome or trisomy ...
... 2009 Elsevier, the leading publisher of scientific, technical ... publishing partnership with The European Association for the Study ... leading European association in the field of liver research. ... flagship journal, the Journal of Hepatology ( ...
... Calif., June 30 Endologix, Inc. (Nasdaq: ELGX ... announced that it has been added to the Russell 3000(R), ... after the close of the U.S. markets. , , ... Endologix is now included in the Russell Indexes, which has ...
Cached Medicine News:Health News:Intelligent Hospital Systems Receives International Award for Innovative Technology Benefiting Society 2Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 2Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 3Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 4Health News:Reduced ovarian reserve associated with increased risk of trisomic pregnancy 2Health News:Reduced ovarian reserve associated with increased risk of trisomic pregnancy 3Health News:Endologix Added to Russell Indexes 2
... Multifunctional instrumentation, capable of comminution, ... by means of ultra-sonic energy. ... organs, and, in particular, parenchymatous ... of tissue-selection and non-traumatic preparation ...
... system is the recognized world leader, ... superior tactile feedback and exceptional visualization ... surgical modality combines tissue fragmentation, irrigation, ... performance in procedures requiring precise, selective ...
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 7.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 8.0 mm and length 7.5 mm....
Medicine Products: